Back to GNVC
GenVec Reports First Quarter 2012 Financial Results

GAITHERSBURG, Md., May 10, 2012 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the first quarter ended March 31, 2012. GenVec reported a net loss of $3.2 million, or $0.25 per share, compared with a net loss of $2.2 million, or $0.17 per share, in the comparable quarter of 2011.

First Quarter and Recent Business Highlights

Hearing Loss and Balance Disorders Program

    --  GenVec extended its Research Collaboration and License Agreement with
        Novartis. Under the extension, Novartis will fund research at GenVec
        through January 2013 to support the Company's hearing loss and balance
        disorders program.

Vaccine Programs

    --  Encouraging preclinical proof of concept data generated in non-human
        primates involving GenVec's respiratory syncytial virus (RSV) vaccine
        program were presented at Keystone Symposia's 2012 Meeting on Viral
        Immunity and Host Gene Influence. GenVec's vaccine technology induced
        neutralizing antibody and significant T-cell responses with a single
        administration. The immune responses were consistent with protective
        responses without disease potentiation, and multiple administrations
        increased the neutralizing antibody responses.

    --  GenVec received a grant of approximately $590,000 over two years from
        the National Institute of Allergy and Infectious Diseases (NIAID) of the
        National Institutes of Health (NIH) to support the Company's RSV vaccine
        program. This grant will be used to further advance the novel pediatric
        RSV vaccine.

    --  GenVec received a grant of $600,000 over two years from the NIAID to
        support the Company's malaria vaccine program. This grant will be used
        to identify novel antigens for malaria vaccine development.
    --  A research paper on GenVec's new vaccine vectors titled "Modification of
        Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5
        Neutralizing Antibodies and Induces Protective Immune Responses" was
        published online in PloS ONE.

Financial Results for the Three Months Ended March 31, 2012

Revenue for the first quarter decreased 40% to $3.2 million from $5.3 million in the same period last year. The decrease for the three-month period ended March 31, 2012, is primarily due to lower revenue associated with our hearing program of $1.8 million. The lower revenue for our hearing program is due mainly to reduced work scope associated with manufacturing activities which were completed in preparation for clinical studies under our Novartis agreements in 2012 as compared to the 2011 period. In addition, there is a $0.4 million decrease due to the recognition of the non-refundable upfront license fee which was fully recognized as of January 2012. Also contributing to the decrease is a reduction in revenue associated with our HIV program of $0.6 million due to reduced work scope. Partially offsetting these decreases are increased revenue associated with grant work performed for our malaria and NIH programs of $0.2 million.

Operating expenses for the first quarter of 2012 decreased 15% to $6.4 million from $7.5 million in the same period last year.

Research and development expenses for the three-month period ended March 31, 2012, decreased 23% to $4.3 million from $5.6 million in 2011. The decrease is primarily due to lower manufacturing and equipment costs associated with our hearing program. Also contributing to a lesser extent are reduced personnel costs due mainly to the termination of our TNFerade trial in March 2010. These decreases are partially offset by increased field safety study costs associated with our foot-and-mouth disease (FMD) program.

General and administrative expenses for the three-month period ended March 31, 2012, increased 6% with an expense of approximately $2.0 million in 2012 as compared to $1.9 million in 2011. During the three-month period ended March 31, 2012, we experienced higher professional costs.

GenVec ended the first quarter of 2012 with $24.2 million in cash, cash equivalents, and short-term investments. "The first quarter of 2012 was a productive period for research with some good accomplishments," commented GenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky. "Based on our current operations, we currently anticipate our cash burn this year will average approximately $2.0 million per quarter."

Conference Call Information

GenVec will hold a conference call today at 10:00 a.m. EDT to discuss the Company's first quarter financial results. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 47685978. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on May 10, 2012 through May 17, 2012. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 47685978.

To access the webcast or the replay, go to, click on "Investors and Media," and click on "Events and Presentations."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to follow)

                           GenVec, Inc.
                Condensed Statements of Operations
               (in thousands, except per share data)

                                           Three Months Ended
                                                  March 31,
                                                 2012                 2011
    Revenues                                   $3,164               $5,286

    Operating expenses:
    Research and development                    4,323                5,592
    General and administrative                  2,044                1,922
                                                -----                -----
        Total operating expenses                6,367                7,514
                                                -----                -----

    Loss from operations                       (3,203)              (2,228)

    Other income:
    Interest income, net                            8                   12
    Other income                                    1                    -
                                                  ---                  ---
    Total other income, net                         9                   12
                                                  ---                  ---

    Net loss                                  $(3,194)             $(2,216)
                                              =======              =======

    Basic and diluted net loss                 $(0.25)              $(0.17)
        per share
    Shares used in computation of
     basic                                     12,938               12,914
        and diluted net loss per share

                           GenVec, Inc.
                Selected Balance Sheet Information
                          (in thousands)

                                       March 31, 2012         December 31,
    Cash, cash equivalents and                $24,158              $26,446
        short-term investments
    Working capital                            22,850               25,739
    Total assets                               26,949               29,866
    Stockholders' equity                       23,679               26,538
    Retail Investor and Media Contact: Institutional Investor Contact:
    GenVec, Inc.                       S.A. Noonan Communications
    Douglas J. Swirsky                 Susan A. Noonan
    (240) 632-5510                     (212) 966-3650      

SOURCE GenVec, Inc.

Copyright (2015) PR Newswire. All Rights Reserved.
Back to GNVC
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki